Brief: Moleculin Announces U.S. Patent Issue Notification For Lipid-Based Delivery Technology For Annamycin
09/05/2024 15:54
May 9 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ANNOUNCES U.S. PATENT ISSUE NOTIFICATION FOR
LIPID-BASED DELIVERY TECHNOLOGY FOR ANNAMYCIN
* MOLECULIN BIOTECH INC - ANNAMYCIN IS ADVANCING TOWARDS
PIVOTAL
AML STUDY IN 2024 AND MAY QUALIFY FOR AN ACCELERATED APPROVAL
PATHWAY
Source text for Eikon: ID:nPn5GxYKka
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM